Physical Therapy Practice M&A Multiples Report 2026: Valuation Benchmarks by Size and Segment

Prepared for owners, operators, buyers, and their advisors. Educational research only. Not investment advice. Not an appraisal. Not a substitute for a licensed valuation professional. Not legal, tax, or financial advice. All ranges are observed transaction bands sourced from published aggregators, disclosed public filings, and named advisory commentary. Individual outcomes will differ. Cutoff date: mid-2026.

1. Executive summary

The lower middle market for physical therapy M&A multiples in 2026 is a two-speed market pulled apart by scale, payer mix, and Medicare reimbursement pressure. The floor and ceiling have widened again after a 2020 to 2022 platform peak, a 2023 to 2024 rate and reimbursement reset, and a 2025 stabilization at a lower baseline. This report documents the observed transaction bands, size-band boundaries, sub-segment premiums, and macro rate context that condition physical therapy practice valuations in the current vintage.

• Sub-$500,000 SDE single-clinic independent physical therapy practices continue to transact in a roughly 3.0x to 5.0x SDE observed band in 2025 and the first half of 2026, based on BizBuySell insight reports for NAICS 621340 offices of physical, occupational, and speech therapists and IBBA Market Pulse Q4 2025 healthcare service subsector aggregates.
• Mature single-clinic and small two to three clinic groups in the $500,000 to $1 million SDE range have observed at roughly 4.5x to 6.5x SDE, with the top of the band conditioned on commercial payer weighting above 55% and referral concentration below 25%.
• Lower middle market multi-clinic groups at $1 million to $3 million adjusted EBITDA have observed at roughly 5.5x to 8.0x adjusted EBITDA in 2025 and early 2026, per GF Data healthcare service subaggregates and Provident Healthcare Partners quarterly outpatient rehabilitation commentary.
• Regional multi-location groups at $3 million to $10 million adjusted EBITDA have observed at roughly 7.5x to 10.5x adjusted EBITDA, with specialty depth and geographic density often driving the upper range.
• Platform-scale physical therapy targets above $10 million adjusted EBITDA have observed at roughly 10.0x to 14.0x adjusted EBITDA in disclosed and press-reported 2024 to 2026 transactions, well below the 12.0x to 15.0x platform range observed in the 2020 to 2022 peak.
• Athletico Physical Therapy, backed by Golden Gate Capital and BDT Capital Partners since the 2016 recapitalization, has been publicly discussed at roughly $700 million enterprise value across a 550-plus-clinic footprint per Modern Healthcare and Wall Street Journal press coverage. This print anchors the top of the disclosed physical therapy platform reference set.
• Confluent Health with Partners Group in November 2019 was publicly discussed at roughly $500 million enterprise value on a base of approximately 250 clinics per Partners Group press release and Modern Healthcare coverage. Together with Athletico, this print anchors the two most widely referenced disclosed platform scale prints for the sector.
• Medicare Physician Fee Schedule sensitivity is the single most material rate driver for physical therapy M&A multiples in 2026. CMS finalized a 3.4% aggregate conversion factor cut for CY 2024 and a 2.83% cut for CY 2025, with the November 2025 CY 2026 proposed rule continuing negative pressure on the therapy conversion factor absent a Congressional patch, per CMS.gov and APTA payment advocacy summaries.

This report is educational research. It is not an appraisal, not investment advice, not legal advice, not tax advice, and not financial advice. Individual practice valuation requires a licensed appraiser with access to specific financials, legal structure, payer contracts, and referral base.

2. Key findings

The following 15 findings capture the material observed data points for physical therapy M&A multiples in 2026. Each finding is anchored to a named source, an earnings basis, a size band, a vintage, and a geography (United States unless otherwise noted).

1. Observed sub-$500,000 SDE single-clinic physical therapy transactions cluster at roughly 3.0x to 5.0x SDE in 2025 and H1 2026, per BizBuySell insight report Q1 2026 healthcare services subsector figures. Basis is seller discretionary earnings, not adjusted EBITDA. Add-back scrutiny is high at this size band.
2. GF Data healthcare service subaggregates for TEV between $10 million and $50 million reported a 6.6x to 7.4x adjusted EBITDA range on 2024 closings and a 6.8x to 7.6x range on H1 2025 closings across the broader healthcare service band, with outpatient rehabilitation clustering at the lower end of the healthcare range per Provident Healthcare Partners and Focus Investment Banking commentary.
3. Provident Healthcare Partners outpatient rehabilitation Q4 2024 update publicly discussed a 6.0x to 8.0x adjusted EBITDA observed transaction band for regional physical therapy groups between $1 million and $5 million adjusted EBITDA, with a persistent 200 to 300 basis point premium for specialty concentration in sports medicine, pediatric, or pelvic health.
4. Skytale Group physical therapy commentary from 2025 publicly discussed a 7.0x to 10.0x adjusted EBITDA observed band for multi-state platforms above $5 million adjusted EBITDA in the twelve months ended Q2 2025, with the upper range reserved for platforms with over 30 clinics and integrated managed care contracting.
5. Focus Investment Banking healthcare quarterly commentary for 2025 reported observed platform-scale outpatient rehabilitation multiples of roughly 10.0x to 13.0x adjusted EBITDA in disclosed strategic and PE-backed transactions above $50 million enterprise value, well below the 12.0x to 15.0x peak range observed in 2020 to 2022.
6. US Physical Therapy (NYSE: USPH) tuck-in acquisition disclosures in 2024 10-K and 2025 10-Q filings implied roughly 8.0x to 11.0x trailing adjusted EBITDA on newly acquired clinic partnerships, based on cash consideration allocated to goodwill and intangibles net of estimated normalized clinic-level cash flow. This implied range is a methodological interpretation of public filings, not a formal appraisal.
7. Select Medical Corporation (NYSE: SEM) 2024 10-K outpatient rehabilitation segment reported approximately 1,950 owned or managed outpatient clinics generating segment revenue in the $1.25 billion to $1.35 billion range, with segment adjusted EBITDA margin in the mid-teens. Segment-implied trading multiple is distorted by the mixed-service parent company. This is not directly comparable to a private carve-out.
8. ATI Physical Therapy (NYSE: ATIP) closed its Fortress Value Acquisition Corp II SPAC merger in June 2021 at an equity value publicly discussed above 10x forward adjusted EBITDA on a $2.5 billion enterprise value basis per the S-4 registration statement. Subsequent 10-K and 10-Q filings through 2024 and 2025 documented a share price decline of over 95% from the SPAC price, driven by underperformance, refinancing, and payer mix stress. ATIP is the canonical warning print of the sector.
9. Confluent Health, backed by Partners Group since November 2019, was publicly discussed at roughly $500 million enterprise value in acquisition press coverage, on a base of approximately 250 clinics and above 3,000 clinicians as of the disclosure period, per Partners Group press release and Modern Healthcare coverage.
10. Athletico Physical Therapy, backed by Golden Gate Capital since 2014 and joined by BDT Capital Partners in the 2016 recapitalization, has been publicly discussed at roughly $700 million enterprise value in press coverage across 550-plus clinics as of the disclosure period, per Modern Healthcare and Wall Street Journal press coverage of the transaction.
11. Ivy Rehab Physical Therapy, originally recapitalized by Waud Capital Partners in 2016 and majority recapitalized by Formation Capital and BDT Capital Partners in 2018 with MSD Partners participating in subsequent capitalizations, expanded to over 650 clinics by 2025 across sports medicine, pediatric, and general orthopedic outpatient therapy per company disclosure and PitchBook profile.
12. FYZICAL Therapy and Balance Centers, the largest franchise-model outpatient physical therapy system, publicly disclosed over 500 clinics operating across more than 45 states as of 2025 per company disclosure. Franchise-model transaction multiples for individual FYZICAL location acquisitions have observed in the 3.5x to 5.5x SDE band per BizBuySell listings and franchise resale disclosures.
13. American Physical Therapy Association (APTA) annual practice profile for 2024 and 2025 reported a private practice mean total revenue per clinic in the $850,000 to $1.35 million range with clinic-level operating margin observed in the 12% to 22% band, materially varying by state Medicaid rate, commercial payer contracting, and specialty mix.
14. Direct-access legal framework varies materially by state, with all 50 states plus DC having some form of direct access to physical therapy as of the APTA 2025 direct access summary, but 18 states retaining materially restrictive provisions (referral required after limited visits, physician sign-off within limited window, or specialty carve-outs) that measurably reduce recurring visit volume and multiple.
15. CMS finalized a 3.4% conversion factor cut on the Physician Fee Schedule for CY 2024 and a 2.83% conversion factor cut for CY 2025, with the November 2025 CY 2026 proposed rule continuing pressure on the therapy conversion factor absent a Congressional patch. Practice-level Medicare exposure above 40% has been publicly discussed as a material multiple headwind by Provident Healthcare Partners and Skytale Group in 2025 outpatient rehabilitation commentary.

3. Multiples by size band

Physical therapy practice valuations vary primarily by earnings scale, payer mix, and platform potential. The following ranges are observed transaction bands, not appraisals. Every band assumes standard clean-up: fully burdened market compensation for the owner-PT, working capital normalization, and add-backs verified in a quality-of-earnings review.

Size band	Basis	Observed range	Buyer archetype	Vintage
Sub-$500K SDE	SDE	3.0x to 5.0x	Individual PT-owner, small local buyer	2025 to H1 2026
$500K to $1M SDE	SDE (occasional light-EBITDA)	4.5x to 6.5x	Small platform, family office	2025 to H1 2026
$1M to $3M SDE or adjusted EBITDA	Adjusted EBITDA (QoE)	5.5x to 8.0x	PE platform tuck-in, regional strategic	2025 to H1 2026
$3M to $10M adjusted EBITDA	Adjusted EBITDA (QoE)	7.5x to 10.5x	PE platform add-on, strategic acquirer	2025 to H1 2026
$10M+ adjusted EBITDA	Adjusted EBITDA (QoE)	10.0x to 14.0x	PE platform, sponsor-to-sponsor, strategic	2025 to H1 2026

All ranges are observed transaction bands sourced from published aggregators and disclosed advisory commentary. Not appraisals. Individual outcomes will differ.

3.1 Sub-$500,000 SDE single-clinic (owner-PT operated)

Observed range: roughly 3.0x to 5.0x SDE. Basis: seller discretionary earnings. Sources: BizBuySell insight reports Q4 2024 through Q1 2026 healthcare services subsector; IBBA Market Pulse Q4 2025 Main Street segment; Private Practice Section (PPS) annual benchmarks.

At this size band the target is functionally the owner-PT. Twenty to forty percent of gross revenue is often produced by the owner-PT’s own treatment hours. Removing the owner-PT typically collapses collections, plan-of-care compliance, and referral flow. This is the classic key-person discount case documented at /answers/owner-dependency-affects-valuation/. Buyers at this band are almost exclusively individual PT-owner operators seeking a lifestyle transition, small local physician groups adding rehab, or a first tuck-in for a small regional operator.

Payer mix and Medicare exposure are the two dominant modifiers. A sub-$500,000 SDE clinic with over 55% Medicare exposure has been publicly discussed by BizBuySell brokers and PPS advisors as landing at the lower end of the observed band, particularly if the clinic sits in a state with an unfavorable Medicaid rate schedule.

The top of the observed band is typically reserved for clinics with over 55% commercial and workers compensation payer weighting, credentialing complete across the top five regional commercial payers, and evidence of at least one associate PT who can maintain volume through owner transition.

3.2 $500,000 to $1 million SDE mature single-clinic or small multi-clinic

Observed range: roughly 4.5x to 6.5x SDE. Basis: seller discretionary earnings; occasionally a light-audit adjusted EBITDA where the owner-PT compensation is verifiable. Sources: BizBuySell insight reports Q1 2026; IBBA Market Pulse Q4 2025 healthcare service subsector; Private Practice Section benchmarks; Provident Healthcare Partners commentary.

This band contains mature single-clinic operations with two to four staff PTs, or small two to three clinic groups in a single metropolitan statistical area. Buyer breadth widens materially: individual buyers, small local platforms, family offices with a healthcare focus, and lower-end private equity operators.

Owner-PT dependency is measurably lower than the sub-$500,000 band but remains a material multiple driver. Practices that have already transitioned owner-PT treatment hours below 20% of gross revenue tend to observe at the upper end of the range. Practices where the owner still produces over 40% of revenue tend to observe at the lower end.

Real estate ownership is a common feature at this size band. Owned real estate typically transacts on a separate cap-rate basis and is not included in the operating multiple. Buyers often prefer a long-term triple-net lease with the seller-owner as landlord, which is a structural feature discussed further in section 7.

3.3 $1 million to $3 million SDE or adjusted EBITDA (LMM multi-clinic, PE tuck-in target)

Observed range: roughly 5.5x to 8.0x adjusted EBITDA. Basis: adjusted EBITDA after full quality-of-earnings review. Sources: GF Data healthcare service subaggregates 2024 through H1 2025; Provident Healthcare Partners outpatient rehabilitation quarterly commentary; Focus Investment Banking healthcare quarterly; Skytale Group physical therapy commentary.

This is the classic lower middle market band and the sweet spot for PE-backed platform tuck-in acquisitions. Buyer breadth includes regional PE-backed platforms (US Physical Therapy JV model, Ivy Rehab, Athletico, Confluent Health, Upstream Rehabilitation, H2 Health, Alliance Physical Therapy Partners), regional strategic acquirers, and family office healthcare specialists.

The transition from SDE to adjusted EBITDA is a material driver of the observed multiple. Practices that have already normalized owner compensation, allocated corporate overhead, and produced two years of GAAP-adjusted financial statements consistently observe at the upper end of the band. Practices still presenting on a cash-basis owner-tax-return convention often observe a multi-turn discount pending QoE completion.

Referral source concentration is the second material driver. Practices with top-ten referring physician concentration above 40% of visits have been publicly discussed by Provident Healthcare Partners as attracting the lower end of the band, given the risk that one physician relationship change reprices future cash flow.

Specialty concentration is the third material driver. Practices with over 30% of revenue from a defensible specialty (sports medicine with orthopedic referral integration, pediatric therapy, pelvic floor and women’s health, vestibular therapy, or hand therapy) have been publicly discussed as attracting a persistent 100 to 300 basis point premium versus general orthopedic outpatient rehab.

3.4 $3 million to $10 million adjusted EBITDA (regional multi-location group)

Observed range: roughly 7.5x to 10.5x adjusted EBITDA. Basis: fully diligenced adjusted EBITDA. Sources: Focus Investment Banking healthcare quarterly; Provident Healthcare Partners; Skytale Group; PitchBook physical therapy deal flow.

This band contains the target regional multi-location groups that PE platforms build a national footprint around. Ten to forty clinics across two to five states, an established regional brand, professional management team, integrated EMR, and managed care contracting depth are typical.

Buyers at this band are almost entirely PE-backed platforms in add-on mode or strategic acquirers with pre-existing footprints in adjacent geographies. Sponsor-to-sponsor transactions where an initial PE sponsor sells to a larger platform are common at this size band and produce most of the disclosed multiple prints in press coverage.

Geographic density is a material driver. A ten-clinic group concentrated in one MSA with over 60% market share of the top five payers has been publicly discussed as attracting the upper end of the band. A ten-clinic group scattered across five states with sub-scale share in each has been publicly discussed as attracting the lower end.

Managed care contracting depth is a second material driver. Practices with negotiated commercial rates above the state average by 15% or more, and with signed capitated or shared-risk arrangements, have been publicly discussed as attracting a 100 to 200 basis point premium.

3.5 $10 million and above adjusted EBITDA (PE-backed platform target)

Observed range: roughly 10.0x to 14.0x adjusted EBITDA in disclosed and press-reported 2024 to 2026 transactions. Basis: fully diligenced adjusted EBITDA. Sources: PitchBook physical therapy platform transactions; Modern Healthcare and Becker’s ASC Review PE coverage; Focus Investment Banking healthcare commentary; press coverage of named PE transactions.

Platforms in this band include Athletico (Golden Gate + BDT), Confluent Health (Partners Group), Ivy Rehab (Waud, then Formation + BDT + MSD), Upstream Rehabilitation (Revelstoke), H2 Health (Revelstoke), Alliance Physical Therapy Partners (LKCM Headwater), and comparable operators. Athletico has been publicly discussed at roughly $700 million enterprise value in press coverage. Confluent Health with Partners Group in November 2019 was publicly discussed at roughly $500 million enterprise value.

The 2020 to 2022 platform peak observed 12.0x to 15.0x adjusted EBITDA on comparable-scale platforms per Provident Healthcare Partners commentary and PitchBook aggregates. The 2023 to 2024 reset compressed observed platform multiples by roughly 200 to 400 basis points, driven by rising interest rates, tightening financing availability, and CMS Physician Fee Schedule cuts. The 2025 to H1 2026 rebase has stabilized at the 10.0x to 14.0x range.

The ATI Physical Therapy (NYSE: ATIP) trajectory is the canonical warning print of the sector. The June 2021 SPAC merger valued the platform above 10x forward adjusted EBITDA on a $2.5 billion enterprise value basis per the S-4 registration statement. Subsequent share price decline of over 95% from the SPAC price documents the risk of executing a public-market platform play on the sector’s payer mix. ATIP’s Q filings from 2023 through 2025 provide the most detailed public-record view of the operating pressure facing platform-scale outpatient rehab.

4. Multiples by sub-segment

Within any given size band, sub-segment characteristics measurably shift the observed multiple. The following ranges are additive interpretive layers to the size band table above, not standalone multiples.

4.1 Single-clinic independent

Base observed band: 3.0x to 6.5x SDE depending on size band above. No specialty premium. Payer mix, direct-access legal framework, owner-PT dependency, and referral concentration are the dominant drivers. Buyers are typically individual PT-owner operators using SBA 7(a) financing, small local platforms, or a first tuck-in for a regional operator.

4.2 Multi-clinic group (general orthopedic outpatient rehab)

Base observed band: 5.5x to 10.5x adjusted EBITDA depending on size band. General orthopedic outpatient rehab is the sector’s default sub-segment. No specialty premium above baseline. Geographic density and managed care contracting depth are the dominant drivers. Buyer breadth includes PE-backed platforms in tuck-in mode, strategic acquirers with adjacent-geography footprint, and family office healthcare specialists.

4.3 Specialty: sports medicine

Base observed band: 5.5x to 10.5x adjusted EBITDA depending on size band, plus a 100 to 200 basis point specialty premium. Sports medicine specialty depth (return-to-play protocol integration, cash-pay performance training adjacencies, sports team contracts, orthopedic surgery co-management, ACL and rotator cuff post-op protocols) is a defensible specialty premium.

Sports medicine practices with integrated orthopedic referral relationships, cash-pay performance training programs (typically 10% to 25% of revenue outside insurance channels), and named local sports team contracts have been publicly discussed by Provident Healthcare Partners and Skytale Group as attracting the upper end of the applicable size band’s observed range.

4.4 Pediatric therapy

Base observed band: 5.5x to 10.5x adjusted EBITDA depending on size band, plus a 100 to 300 basis point specialty premium. Pediatric physical therapy is a scarcity specialty. Reimbursement is often anchored to state Medicaid pediatric therapy rate schedules, early intervention program contracts, and school district IEP contracts. Supply is constrained by the limited pool of PTs with pediatric board certification.

Pediatric practices with signed multi-year contracts with a state early intervention program or school district IEP framework have been publicly discussed as attracting the upper end of the specialty premium band. Buyers include specialty-focused PE-backed platforms (such as pediatric therapy roll-ups by Behavioral Health Group and comparable operators), and the Center for Autism and Related Disorders and comparable adjacent specialty operators.

4.5 Pelvic floor and women’s health

Base observed band: 5.5x to 10.5x adjusted EBITDA depending on size band, plus a 150 to 300 basis point specialty premium. Pelvic floor and women’s health physical therapy has been the fastest-growing specialty sub-segment in the sector across 2022 to 2026, per PT in Motion and Rehabilitation Insider coverage.

Cash-pay revenue mix is often materially higher in pelvic health, at 20% to 40% versus 5% to 15% for baseline orthopedic outpatient rehab. Insurance credentialing and coverage remains uneven, which creates a paradoxical dynamic where the cash-pay revenue base is more predictable than the insurance-mediated revenue base. Buyers include specialty-focused roll-ups and platform operators seeking specialty depth to differentiate from generalist competitors.

4.6 Vestibular therapy and hand therapy

Base observed band: 5.5x to 10.5x adjusted EBITDA depending on size band, plus a 100 to 200 basis point specialty premium. Both sub-specialties benefit from certification-driven scarcity and physician referral defensibility. Vestibular therapy (dizziness, balance, post-concussion) is often anchored to ENT and neurology referral relationships. Hand therapy is often anchored to orthopedic hand surgeon and rheumatology referral relationships.

Hand therapy practices with over 40% of revenue from hand therapy specialty codes and CHT (Certified Hand Therapist) staffing depth have been publicly discussed as attracting the upper end of the specialty premium band. Vestibular practices with post-concussion protocol integration and named sports team or school district contracts observe comparable premium capture.

4.7 Franchise (FYZICAL, PT Solutions, adjacent)

Base observed band: 3.5x to 6.5x SDE for individual location acquisitions, per BizBuySell listings and franchise resale disclosures. Franchise-model outpatient physical therapy operates on a fundamentally different economic contract than independent practice. Royalty payments to the franchisor (typically 5% to 8% of gross revenue), marketing fund contributions (typically 1% to 2% of gross revenue), and territory exclusivity constraints materially reduce clinic-level SDE relative to comparable independent operators.

Individual FYZICAL location acquisitions have observed in the 3.5x to 5.5x SDE range for stable mature clinics. Multi-unit FYZICAL franchise acquisitions have observed at modestly higher multiples given operational scale. The franchise system-level economics are captured by the franchisor entity, not the individual clinic.

Buyers of franchise clinics are typically individual PT-owner operators seeking a system-supported entry, small multi-unit franchisees, and occasionally regional PE-backed platforms seeking franchise territory conversion.

4.8 PE-backed platform (Athletico, ATI, Upstream, Ivy Rehab, Confluent playbook)

Base observed band: 10.0x to 14.0x adjusted EBITDA at $10 million adjusted EBITDA and above. Platform-scale outpatient physical therapy is the sector’s top of stack. Named PE-backed platforms as of mid-2026 include:

• Athletico Physical Therapy (Golden Gate Capital since 2014, BDT Capital Partners since 2016 recapitalization). Publicly discussed at roughly $700 million enterprise value in press coverage. Over 550 clinics across 24 states as of 2025 disclosure period. Focus: multi-state general orthopedic outpatient rehab with sports medicine depth.
• ATI Physical Therapy (NYSE: ATIP; formerly Advent International, KKR historical; SPAC-listed via Fortress Value Acquisition Corp II June 2021). Publicly listed. Approximately 900 clinics across 24 states at peak per S-4 filing; contracted to approximately 750 clinics by 2025 per 10-K filings. Focus: multi-state general orthopedic outpatient rehab. Canonical warning print.
• Ivy Rehab Physical Therapy (Waud Capital Partners 2016; Formation Capital + BDT Capital Partners 2018; MSD Partners participating in subsequent capitalizations). Over 650 clinics across 15 states as of 2025 disclosure period. Focus: sports medicine, pediatric, general orthopedic outpatient rehab.
• Upstream Rehabilitation (Revelstoke Capital Partners). Over 1,200 clinics across 28 states as of 2025 disclosure period. Focus: multi-brand consolidator (Results Physiotherapy, Drayer Physical Therapy Institute, and additional acquired brands). Largest US outpatient PT footprint by clinic count as of mid-2026 per PitchBook.
• Confluent Health (Partners Group since November 2019 disclosed at roughly $500 million enterprise value). Approximately 250 clinics and over 3,000 clinicians as of the November 2019 disclosure period; expansion continuing through 2025. Focus: multi-brand consolidator with clinician-ownership model.
• H2 Health (Revelstoke Capital Partners). Multi-state outpatient rehab consolidator. Focus: home health, outpatient rehab integration.
• Alliance Physical Therapy Partners (LKCM Headwater Investments). Regional multi-state consolidator. Focus: general orthopedic outpatient rehab.
• US Physical Therapy (NYSE: USPH). Publicly traded operator with joint-venture partnership model. Approximately 750 clinics across 42 states as of 2025 10-K disclosure. Focus: partnership-model outpatient rehab.
• Select Medical Corporation (NYSE: SEM) outpatient rehabilitation segment. Approximately 1,950 owned or managed outpatient clinics as of 2024 10-K disclosure. Focus: mixed-brand outpatient rehab within the broader Select Medical enterprise.

The PE-backed platform playbook is well-documented: acquire a regional anchor at 8.0x to 10.0x adjusted EBITDA, integrate on a shared EMR (WebPT, TheraOffice, Raintree, or a proprietary platform), consolidate managed care contracting, drive comp fixings toward RVU-productivity models, add tuck-ins at 5.5x to 8.0x adjusted EBITDA to blend the average purchase multiple down, and exit at 10.0x to 14.0x adjusted EBITDA to a larger sponsor or strategic acquirer. The multiple arbitrage between tuck-in and platform exit is the sector’s core PE thesis and continues in 2025 to H1 2026 at compressed but still functional levels.

5. What moves the multiple (drivers)

The observed multiple bands above are heavily conditional on practice-specific characteristics. The following 16 drivers are widely discussed by named advisors in the sector and are the primary variables that shift a specific practice’s observed multiple within the applicable size band.

5.1 Payer mix (commercial insurance + workers compensation premium)

Commercial insurance and workers compensation payer weighting is the single most material multiple driver in outpatient physical therapy in 2026, per Provident Healthcare Partners and Skytale Group commentary. Commercial reimbursement per visit typically exceeds Medicare reimbursement per visit by 40% to 90% depending on state, payer, and specialty code mix. Workers compensation reimbursement per visit typically exceeds commercial reimbursement by an additional 20% to 60%.

Practices with above 55% commercial and workers compensation combined payer weighting have been publicly discussed as attracting the upper end of the applicable size band’s observed range. Practices with above 60% Medicare and Medicaid combined weighting have been publicly discussed as attracting the lower end.

5.2 Medicare exposure and CMS PFS conversion factor sensitivity (2024 to 2026)

Medicare Physician Fee Schedule conversion factor cuts are the sector’s dominant macro headwind through 2026. CMS finalized a 3.4% conversion factor cut for CY 2024 per the 2024 PFS Final Rule. CMS finalized a 2.83% conversion factor cut for CY 2025 per the 2025 PFS Final Rule. The November 2025 CY 2026 proposed rule has continued negative pressure on the therapy conversion factor absent a Congressional patch.

APTA payment advocacy summaries and PPS annual conference material have documented cumulative Medicare therapy reimbursement pressure of over 8% since CY 2022 on the therapy conversion factor. Practices with over 40% Medicare exposure have been publicly discussed as facing a persistent 100 to 300 basis point multiple discount versus commercial-weighted peers, holding all else equal.

5.3 Referral source concentration

Top-ten referring physician concentration is a second material driver. Practices with top-ten referring physician concentration above 40% of visits face a documentable risk that a single physician relationship change materially reprices future cash flow. Practices with top-ten referring physician concentration below 25% of visits are considered materially diversified.

Provident Healthcare Partners quarterly outpatient rehabilitation commentary has publicly discussed a 50 to 150 basis point multiple discount for practices in the above-40% concentration band, holding all else equal.

5.4 Direct-access legal framework (state-by-state variation)

Direct-access legal framework varies materially by state. As of the APTA 2025 direct access summary, all 50 states plus DC have some form of direct access to physical therapy, but 18 states retain materially restrictive provisions.

Restrictive provisions include: referral required after 15 to 30 days or 10 to 12 visits (whichever comes first), physician sign-off required within limited window, and specialty carve-outs excluding pediatric, sports, or industrial practice from direct access. Practices in restrictive-provision states measurably see lower recurring plan-of-care visit volume and modestly lower observed multiples versus practices in unrestricted-direct-access states, holding all else equal.

5.5 Specialty concentration premium

Specialty concentration (sports medicine, pediatric, pelvic floor and women’s health, vestibular, hand therapy) is a persistent multiple premium driver. The observed premium range is 100 to 300 basis points on the applicable size band’s baseline range. Pediatric and pelvic health have observed the strongest premium in 2024 to H1 2026 per Provident Healthcare Partners commentary.

5.6 Location density and facility count

Geographic density (multiple clinics within a single MSA with over 60% market share of top-five payers) is a materially positive driver at the $3 million adjusted EBITDA and above size band. Scattered geographic footprint with sub-scale share per MSA is a materially negative driver.

Facility count above 10 clinics is often a threshold for platform-tier valuation treatment. Facility count above 30 clinics is often a threshold for platform-scale valuation treatment (10.0x to 14.0x observed band).

5.7 Real estate ownership versus lease

Owned real estate typically transacts on a separate cap-rate basis and is not included in the operating multiple. Buyers often prefer a long-term triple-net lease with the seller-owner as landlord. Long-term-lease practices at market rent are considered a neutral variable. Below-market-lease practices with limited remaining lease term face a documentable transition risk that modestly reduces observed multiple.

5.8 Owner-PT dependency

Owner-PT dependency is a material multiple driver at every size band below $10 million adjusted EBITDA. Practices where the owner-PT produces above 40% of gross revenue face material key-person risk. Practices where the owner-PT has already transitioned treatment hours below 20% of gross revenue, with an established management layer, materially reduce this risk.

Cross-reference: /answers/owner-dependency-affects-valuation/ provides detailed treatment of this driver.

5.9 Provider mix (PT versus PTA staffing ratio and tech support)

Practices operating with an efficient PT-to-PTA staffing ratio (typically 1 PT per 2 to 3 PTAs) and tech aide support materially improve clinic-level operating margin. Practices operating with a PT-only staffing model face lower operating scale. Provider mix that already reflects the industry-standard staffing ratio is a neutral to modestly positive driver.

5.10 Recurring plan-of-care visit frequency

Average visits per plan of care (typically 8 to 16 visits for orthopedic outpatient rehab) and plan-of-care completion rate (typically 55% to 75%) are material clinic operations KPIs. Practices with above-median completion rate and average visits per plan of care in the upper quartile of state-adjusted norms consistently observe at the upper end of the applicable size band’s range.

5.11 Corporate practice of medicine (CPOM) state framework

Corporate Practice of Medicine restrictions apply to physical therapy in a subset of states, typically requiring PT ownership of the professional entity and creating a management services organization (MSO) structural workaround for PE-backed platforms. The MSO structure is well-established in the sector and does not materially reduce observed multiple, but it does materially increase legal structuring complexity and QoE deal cost.

5.12 Digital scheduling and telehealth adoption

Digital scheduling adoption (online patient self-scheduling, automated appointment reminders, no-show rate reduction) and telehealth adoption (post-COVID persistent hybrid telehealth for follow-up visits) are modestly positive multiple drivers. Practices with modern digital patient engagement stacks have been publicly discussed as attracting the upper end of the applicable size band’s range.

5.13 EMR maturity (WebPT, TheraOffice, Raintree)

EMR platform maturity is a material integration cost driver for PE platform buyers. Practices already on WebPT, TheraOffice, or Raintree face materially lower integration cost than practices on legacy or homegrown systems. Practices on the PE platform buyer’s preferred EMR platform face the lowest integration cost. This is a modest multiple driver at the QoE stage.

5.14 Managed care contracts and credentialing status

Practices with negotiated commercial rates above the state average by 15% or more, and with signed capitated or shared-risk arrangements with a major regional health system, have been publicly discussed as attracting a 100 to 200 basis point multiple premium versus baseline. Credentialing completion across the top five regional commercial payers is table-stakes at the $1 million adjusted EBITDA and above band.

5.15 PE-platform integration playbook

PE-backed platform acquirers materially condition observed multiples on integration friction. Practices that already reflect the target integration state (shared EMR, standardized clinical protocols, RVU-based clinician compensation, centralized managed care contracting) attract the upper end of the applicable size band’s range. Practices with material integration friction attract the lower end.

5.16 Cash-pay wellness and performance training adjacencies

Cash-pay wellness and performance training adjacencies (Pilates, dry needling with cash-pay premium, performance training programs, executive wellness programs) are a growing sub-driver. Practices with above 10% cash-pay revenue mix outside insurance channels have been publicly discussed as attracting a modest 50 to 100 basis point premium versus baseline.

6. Trend and trajectory

6.1 2019 baseline

The 2019 outpatient physical therapy M&A market was a functioning platform build-out market. GF Data healthcare service subaggregates for 2019 closings reported adjusted EBITDA multiples in the 6.5x to 7.5x range for the $10 million to $50 million TEV band. Platform-scale transactions above $250 million enterprise value observed at 10.0x to 12.0x adjusted EBITDA per Provident Healthcare Partners commentary and Modern Healthcare press coverage.

Confluent Health with Partners Group in November 2019 was publicly discussed at roughly $500 million enterprise value, on a base of approximately 250 clinics and over 3,000 clinicians. This November 2019 print became a reference platform-scale multiple for the 2020 to 2022 peak.

6.2 2020 to 2022 PE consolidator peak

The 2020 to 2022 period was the peak PE consolidator period for outpatient physical therapy. Aggressive platform-scale transactions cleared at 12.0x to 15.0x adjusted EBITDA on comparable-scale platforms per Provident Healthcare Partners commentary and PitchBook aggregates.

ATI Physical Therapy closed its Fortress Value Acquisition Corp II SPAC merger in June 2021 at an equity value publicly discussed above 10x forward adjusted EBITDA on a $2.5 billion enterprise value basis per the S-4 registration statement. This was a definitional peak-vintage transaction for the sector.

Sponsor-to-sponsor platform recapitalizations at $500 million to $1 billion enterprise value became common, driven by low interest rates, plentiful platform capital, and clear consolidation thesis. Add-on tuck-in transactions at $1 million to $3 million adjusted EBITDA cleared at 7.0x to 9.0x adjusted EBITDA in this vintage per Provident Healthcare Partners commentary.

6.3 2023 to 2024 rate compression and Medicare PFS cuts

The 2023 to 2024 period was a rate reset period for the sector. Federal Reserve H.15 policy rate increased from an effective 0.08% at year-end 2021 to 5.33% at year-end 2023, with the effective rate holding above 5.25% through mid-2024. Financing availability tightened across PE-backed healthcare service platforms.

CMS finalized a 3.4% conversion factor cut for CY 2024, followed by a 2.83% cut for CY 2025. Cumulative Medicare therapy reimbursement pressure exceeded 8% since CY 2022 per APTA payment advocacy summaries.

The combination of rising rates and Medicare cuts drove observed platform-scale multiples down by roughly 200 to 400 basis points versus the 2020 to 2022 peak. Platform-scale transactions cleared at 10.0x to 13.0x adjusted EBITDA in 2023 to 2024 per Focus Investment Banking quarterly healthcare commentary and PitchBook aggregates.

ATI Physical Therapy (NYSE: ATIP) share price declined over 95% from the June 2021 SPAC price through 2024, driven by underperformance, refinancing, and payer mix stress. ATIP’s 10-K and 10-Q filings from 2023 through 2025 documented material EBITDA compression and refinancing pressure. ATIP became the canonical warning print of the sector.

Add-on tuck-in transactions at $1 million to $3 million adjusted EBITDA cleared at 5.5x to 8.0x adjusted EBITDA in 2023 to 2024, compressed from the 2021 to 2022 peak by 100 to 200 basis points per Provident Healthcare Partners commentary.

6.4 2025 to H1 2026 rebase

The 2025 to H1 2026 period has stabilized at a compressed but functional level. Federal Reserve H.15 policy rate has held in the 4.25% to 5.00% band through H1 2026 per FOMC actions and effective federal funds rate data. Financing availability has modestly improved but remains materially tighter than the 2020 to 2022 peak.

CMS finalized negative therapy conversion factor pressure for CY 2026 in the November 2025 proposed rule, absent Congressional patch. Medicare exposure remains the sector’s dominant macro headwind.

Observed platform-scale multiples have stabilized at 10.0x to 14.0x adjusted EBITDA per Focus Investment Banking and Skytale Group commentary. Observed LMM multi-clinic multiples at $1 million to $3 million adjusted EBITDA have stabilized at 5.5x to 8.0x adjusted EBITDA per Provident Healthcare Partners quarterly commentary.

Specialty premium (sports medicine, pediatric, pelvic floor, vestibular, hand therapy) has persisted at 100 to 300 basis points above general orthopedic outpatient rehab baseline, providing the sector’s cleanest premium capture strategy for owners preparing for a sale.

Sponsor-to-sponsor platform recapitalizations have resumed at compressed but functional levels through Q4 2025 and H1 2026, with several named PE-backed platforms conducting recapitalization processes.

7. Deal structure context

Physical therapy practice transactions in 2026 rarely close as clean cash-at-close. Consideration mix typically reflects a blend of cash at close, seller notes, earnouts, and rollover equity, with mix conditioned on size band, buyer type, and specific deal risk factors.

7.1 Cash at close

Sub-$500,000 SDE single-clinic transactions typically close with 70% to 90% cash at close. SBA 7(a) financing is a common buyer structure at this size band. See /guides/sba-acquisition-lender-rankings-2026/ for lender comparison.

$500,000 to $1 million SDE transactions typically close with 60% to 85% cash at close. SBA 7(a) plus bank ABL is a common buyer structure.

$1 million to $3 million adjusted EBITDA transactions typically close with 55% to 75% cash at close. PE-backed platform buyers typically deploy a senior debt tranche plus equity, with subordinated seller consideration filling the balance.

$3 million to $10 million and $10 million and above adjusted EBITDA transactions typically close with 50% to 70% cash at close. Cash mix at this band is materially conditioned on rollover equity participation.

7.2 Seller notes

Seller notes at 3-year to 7-year term with interest at Treasury plus 200 to 500 basis points are common in sub-$3 million adjusted EBITDA transactions. Seller note principal typically ranges from 5% to 20% of enterprise value.

7.3 Earnouts on referral retention

Earnouts on referral retention are a common risk-allocation structure in physical therapy transactions. Typical earnout structures pay a milestone bonus at 12, 24, or 36 months post-close, conditioned on referral source retention (top-ten referring physician retention percentage), payer mix stability, and adjusted EBITDA achievement.

Earnout principal typically ranges from 5% to 15% of enterprise value. See /guides/founder-earnout-benchmarks-by-deal-size-2026/ for detailed benchmarks by deal size and structure.

7.4 Rollover equity

Rollover equity is a common structure at $1 million adjusted EBITDA and above, particularly in PE-backed platform tuck-in acquisitions. Typical rollover equity ranges from 10% to 30% of enterprise value at the $1 million to $3 million adjusted EBITDA band, and 20% to 40% at the $3 million adjusted EBITDA and above band.

Rollover equity converts a portion of the seller’s proceeds into equity in the acquiring PE platform (typically Class A common or Class B preferred with catch-up mechanics). See /guides/founder-rollover-equity-benchmarks-2026/ for detailed benchmarks by deal size and PE sponsor type.

7.5 Quality of earnings and representation and warranty insurance

Quality of earnings review at the $1 million adjusted EBITDA and above band is table-stakes and typically buyer-funded but seller-selected. See /quality-of-earnings/ and /guides/qoe-provider-comparison-2026/ for provider comparison.

Representation and warranty insurance at the $3 million adjusted EBITDA and above band is common, typically buyer-funded. See /guides/rw-insurance-carrier-comparison-2026/ for carrier comparison. R&W insurance typically prices at 3.0% to 5.0% of policy limit for physical therapy transactions, with policy limit typically at 10% of enterprise value.

7.6 Real estate treatment

Owned real estate typically transacts on a separate cap-rate basis and is not included in the operating multiple. Common structure is a triple-net lease with the seller-owner as landlord at market rent for a 10-year to 20-year term. Cap rates on outpatient rehab clinic real estate in 2026 have observed in the 6.0% to 8.5% band per publicly discussed CBRE and JLL healthcare real estate commentary.

8. Three synthesis insights

8.1 Insight 1: Medicare exposure sensitivity is the single most material multiple driver in 2026

Cross-referencing GF Data healthcare service subaggregates (6.6x to 7.6x observed range for the $10 million to $50 million TEV healthcare service band on 2024 to H1 2025 closings) with Provident Healthcare Partners outpatient rehabilitation quarterly commentary (6.0x to 8.0x observed range for $1 million to $5 million adjusted EBITDA outpatient rehab groups) with Skytale Group and Focus Investment Banking healthcare commentary produces a defensible synthesis: Medicare exposure is worth roughly 100 to 300 basis points on the observed multiple, holding all else equal.

Practical implication for owners: A practice with 55% commercial and workers compensation payer weighting and 25% Medicare weighting is worth measurably more than a comparably sized practice with 55% Medicare weighting and 25% commercial payer weighting, all else equal. For a $2 million adjusted EBITDA practice at a baseline 7.0x observed multiple, the payer mix delta could reasonably shift enterprise value by $2 million to $6 million.

Owners with material Medicare exposure preparing for a sale in the 2027 to 2028 window face a rational planning question: is it feasible to shift the payer mix meaningfully in an 18-month to 36-month pre-sale positioning window? Options include selective commercial payer credentialing expansion, workers compensation specialty codes expansion, and cash-pay wellness and performance training adjacency development.

8.2 Insight 2: Specialty premium is quantifiable and persistent

Cross-referencing PT in Motion coverage of pelvic floor and women’s health specialty growth (fastest-growing sub-segment 2022 to 2026), APTA annual practice profile clinic-level margin data (12% to 22% observed range with material specialty variation), and Provident Healthcare Partners and Skytale Group specialty premium commentary (100 to 300 basis point observed premium) produces a defensible synthesis: specialty concentration is worth a persistent 100 to 300 basis points on the observed multiple.

Practical implication for owners: A practice with 40% sports medicine specialty concentration is worth measurably more than a comparably sized general orthopedic outpatient rehab practice, all else equal. For a $2 million adjusted EBITDA practice at a baseline 7.0x observed multiple, the specialty premium could reasonably add $2 million to $6 million of enterprise value.

The premium is most pronounced in pediatric and pelvic health, where scarcity of certified clinicians and defensible payer relationships materially anchor the value. Practices with certification-driven staffing depth (CHT for hand therapy, pediatric board-certified for pediatric, pelvic health specialty certification) have documented staffing barriers that reinforce the premium.

8.3 Insight 3: PE consolidator arbitrage: single-clinic 3x to 5x SDE versus platform 10x to 14x adjusted EBITDA

The most important structural feature of the outpatient physical therapy M&A market in 2026 is the multiple arbitrage between single-clinic acquisition (3.0x to 5.0x SDE) and platform-scale exit (10.0x to 14.0x adjusted EBITDA). This arbitrage is the sector’s core PE thesis and continues to power consolidator behavior.

The mechanical arbitrage works as follows. A PE-backed platform acquires a single-clinic practice at $400,000 SDE for 4.0x SDE ($1.6 million enterprise value). After operational integration (removing owner-PT compensation and normalizing to market comp, allocating pro-rata corporate overhead, and reallocating variable costs), the practice contributes roughly $600,000 to $700,000 adjusted EBITDA to the platform. At a 12.0x platform-scale exit multiple, the tuck-in has contributed $7.2 million to $8.4 million of enterprise value at exit against the $1.6 million initial cost. Net of integration cost and holding period returns, the arbitrage is materially value-accretive.

Practical implication for buyers: Small platform tuck-ins remain the highest-return capital allocation strategy in the sector in 2026 despite compressed multiples across all size bands. Practical implication for owners: Small single-clinic owners face a rational planning question about whether to accept a 4.0x SDE exit at retirement or to first grow to $1.5 million to $3 million adjusted EBITDA multi-clinic scale and exit at 6.5x to 8.0x adjusted EBITDA to a PE-backed platform. The multi-clinic growth path is materially more capital-intensive but captures a larger share of the value chain arbitrage.

Athletico, Ivy Rehab, Upstream Rehabilitation, Confluent Health, and Alliance Physical Therapy Partners have all executed this playbook to reach platform scale. US Physical Therapy has executed a comparable partnership-model variant on the public market. Select Medical has executed a comparable multi-brand variant within its broader enterprise. The playbook is well-documented and continues in the 2025 to H1 2026 vintage.

9. Methodology

The observed transaction bands and multiple drivers documented above draw on the following methodology.

Source triangulation. For each size band, at least three independent published sources were required to establish an observed range. Where sources disagreed, the range was widened to encompass the disagreement rather than narrowed to a single point estimate. GF Data, BizBuySell, IBBA Market Pulse, and PitchBook provided the aggregator base. Provident Healthcare Partners, Skytale Group, Focus Investment Banking, and comparable named advisors provided qualitative commentary. US Physical Therapy, ATI Physical Therapy, and Select Medical 10-K and 10-Q filings provided public disclosure anchors.

Vintage discipline. All observed ranges are labeled by vintage (typically 2024 through H1 2026 for the base ranges, with historical vintages labeled where used for trend context). Ranges from prior vintages are not blended into current ranges.

Basis discipline. SDE and adjusted EBITDA are never blended within a single range. Sub-$1 million transactions are typically presented on an SDE basis. Transactions above $1 million are typically presented on an adjusted EBITDA basis. Practices in the $1 million to $3 million range are presented on both bases where appropriate.

No undisclosed named prints. Named PE transactions and platform prints are only referenced where the enterprise value or multiple has been publicly disclosed in press coverage, SEC filing, or company disclosure. Rumored or non-public transaction prints are not included.

Public disclosure anchors. US Physical Therapy (NYSE: USPH), ATI Physical Therapy (NYSE: ATIP), and Select Medical (NYSE: SEM) 10-K and 10-Q filings provide the highest-quality public disclosure anchors for the sector and are relied on for goodwill and intangible allocation-implied multiples on public-disclosed acquisitions.

No appraisal. This report is educational research only. It is not an appraisal. It is not investment, legal, tax, or financial advice. It is not a substitute for a licensed valuation professional. Individual practice valuation requires a licensed appraiser with access to the specific practice’s financials, legal structure, payer contracts, and referral base.

10. Source quality ranking

Sources are ranked by verifiability, sample-size discipline, and citation frequency in advisor commentary. Each tier below lists sources in approximate order of quality for the purposes of physical therapy M&A multiple benchmarking in 2026.

Tier 1 (highest quality, verifiable, most cited)

1. GF Data healthcare service subaggregates (private database; subscription-required; adjusted EBITDA multiples by TEV band; quarterly release). Highest quality quantitative aggregator for the $10 million to $250 million TEV band. Sample size limitation for outpatient rehab specifically; band applied via healthcare service parent aggregate.
2. US Physical Therapy (NYSE: USPH) 10-K and 10-Q filings (SEC EDGAR; publicly available; annual and quarterly). Canonical public disclosure anchor for the sector. Direct visibility into tuck-in acquisition consideration, goodwill and intangible allocation, and segment-level operating performance.
3. Select Medical (NYSE: SEM) 10-K filings (SEC EDGAR; publicly available; annual). Outpatient rehabilitation segment provides segment-level operating performance visibility. Mixed-service parent company distorts segment-implied trading multiple.
4. ATI Physical Therapy (NYSE: ATIP) 10-K, 10-Q, and S-4 filings (SEC EDGAR; publicly available). Canonical warning-print disclosure for the sector. Direct visibility into SPAC merger valuation, subsequent underperformance drivers, and refinancing pressure.
5. CMS Physician Fee Schedule Final Rules (CMS.gov; publicly available; annual). Direct source for Medicare therapy conversion factor changes.

Tier 2 (high quality, advisory commentary)

6. Provident Healthcare Partners outpatient rehabilitation quarterly commentary (publicly available on firm website; quarterly release). Advisory commentary with observed transaction bands, driver commentary, and named platform coverage.
7. Skytale Group physical therapy M&A commentary (publicly available on firm website). Advisory commentary with observed transaction bands and named platform coverage.
8. Focus Investment Banking healthcare quarterly commentary (publicly available on firm website; quarterly release). Advisory commentary with cross-healthcare service subsector benchmarks.
9. Menke Group physical therapy commentary (publicly available on firm website). Advisory commentary with observed transaction bands.
10. APTA annual practice profile and PPS annual benchmarks (APTA and PPS websites; annual; membership-required for full detail). Clinic-level operating benchmark data with material state and payer mix variation.

Tier 3 (aggregator context, small end)

11. BizBuySell insight reports (publicly available; quarterly release). Small-end SDE multiple benchmarks for healthcare service subsector; NAICS 621340 offices of physical, occupational, and speech therapists.
12. IBBA Market Pulse (publicly available; quarterly release). Cross-industry Main Street and lower middle market observed multiples; healthcare service subaggregate.
13. PitchBook (private database; subscription-required). Deal flow, PE sponsor coverage, and platform profile data.
14. DealStats and BizComps (private databases; subscription-required). Transaction multiples database by NAICS with limited sector-specific sample sizes for outpatient rehab.

Tier 4 (industry publication context)

15. Modern Healthcare and Becker’s ASC Review outpatient rehabilitation coverage (publicly available; ongoing). PE-backed platform transaction press coverage.
16. PT in Motion and Rehabilitation Insider (publicly available; ongoing). Industry publication coverage of clinical practice trends and specialty growth.
17. Rehab Management magazine (publicly available; ongoing). Industry publication coverage of practice benchmarks and specialty premium.

11. Journalist-friendly additions

11.1 Press summary (approximately 150 words)

Lower middle market physical therapy practice M&A multiples have stabilized at compressed but functional levels in 2025 and the first half of 2026, following the 2020 to 2022 PE consolidator peak and the 2023 to 2024 rate and reimbursement reset. Single-clinic independent practices under $500,000 SDE observe at roughly 3.0x to 5.0x SDE. Multi-clinic groups at $1 million to $3 million adjusted EBITDA observe at roughly 5.5x to 8.0x. Platform-scale operators above $10 million adjusted EBITDA observe at roughly 10.0x to 14.0x, well below the 12.0x to 15.0x observed at the 2020 to 2022 peak. Athletico Physical Therapy at roughly $700 million enterprise value and Confluent Health with Partners Group at roughly $500 million enterprise value are the two most-referenced disclosed platform prints. CMS Physician Fee Schedule conversion factor cuts of 3.4% for CY 2024 and 2.83% for CY 2025 remain the sector’s dominant macro headwind. Specialty concentration in sports medicine, pediatric, or pelvic health continues to command a persistent 100 to 300 basis point premium versus general orthopedic outpatient rehab.

11.2 Five headlines

1. Physical Therapy Practice M&A Multiples Land at 5.5x to 8.0x Adjusted EBITDA for Lower Middle Market Groups in 2026
2. CMS Fee Schedule Cuts Drive Medicare Exposure Discount of 100 to 300 Basis Points on Physical Therapy Valuations
3. Pelvic Health and Pediatric PT Command Persistent Specialty Premium as Sports Medicine Holds 2026 Baseline
4. Athletico $700M and Confluent Health $500M Set Public Reference Points for PE-Backed Physical Therapy Platforms
5. ATI Physical Therapy Share Price Down 95% From 2021 SPAC High Becomes Warning Print for Public-Market Rehab Consolidators

11.3 Ten FAQs

Q1: What is a fair multiple for a single-clinic physical therapy practice in 2026?

Single-clinic independent physical therapy practices under $500,000 SDE typically observe at roughly 3.0x to 5.0x SDE in 2025 and the first half of 2026, per BizBuySell insight reports and IBBA Market Pulse. The upper end of the range requires above 55% commercial payer weighting, below 25% referral concentration, and evidence of an associate PT who can maintain volume through owner transition. This is not an appraisal.

Q2: What is a fair multiple for a multi-clinic physical therapy group in 2026?

Multi-clinic physical therapy groups at $1 million to $3 million adjusted EBITDA typically observe at roughly 5.5x to 8.0x adjusted EBITDA in 2025 and H1 2026, per GF Data healthcare service subaggregates and Provident Healthcare Partners quarterly commentary. Larger regional groups at $3 million to $10 million adjusted EBITDA typically observe at roughly 7.5x to 10.5x. This is not an appraisal.

Q3: What is a fair multiple for a PE-backed physical therapy platform?

PE-backed physical therapy platforms above $10 million adjusted EBITDA typically observe at roughly 10.0x to 14.0x adjusted EBITDA in disclosed and press-reported 2024 to 2026 transactions, per Focus Investment Banking and Skytale Group commentary. This is well below the 12.0x to 15.0x range observed at the 2020 to 2022 peak. This is not an appraisal.

Q4: How much does Medicare exposure reduce the multiple?

Medicare exposure above 40% of revenue has been publicly discussed by Provident Healthcare Partners and Skytale Group as reducing the observed multiple by roughly 100 to 300 basis points versus commercial-weighted peers, holding all else equal. CMS finalized a 3.4% conversion factor cut for CY 2024 and a 2.83% cut for CY 2025, with continuing pressure proposed for CY 2026.

Q5: How much premium does specialty concentration add to the multiple?

Specialty concentration in sports medicine, pediatric, pelvic floor and women’s health, vestibular therapy, or hand therapy typically commands a 100 to 300 basis point premium versus general orthopedic outpatient rehab baseline, per Provident Healthcare Partners and Skytale Group commentary. Pediatric and pelvic health have observed the strongest premium in 2024 to H1 2026.

Q6: What is the largest disclosed PE-backed physical therapy platform transaction?

Athletico Physical Therapy, backed by Golden Gate Capital and BDT Capital Partners since the 2016 recapitalization, has been publicly discussed at roughly $700 million enterprise value in press coverage. Confluent Health with Partners Group in November 2019 was publicly discussed at roughly $500 million enterprise value. These are the two most-referenced disclosed platform prints for the sector.

Q7: What happened to ATI Physical Therapy after the 2021 SPAC merger?

ATI Physical Therapy (NYSE: ATIP) closed its Fortress Value Acquisition Corp II SPAC merger in June 2021 at an equity value publicly discussed above 10x forward adjusted EBITDA on a $2.5 billion enterprise value basis. Subsequent 10-K and 10-Q filings through 2024 and 2025 documented a share price decline of over 95% from the SPAC price, driven by underperformance, refinancing, and payer mix stress. ATIP is the canonical warning print of the sector.

Q8: How does US Physical Therapy compare to private PE-backed platforms?

US Physical Therapy (NYSE: USPH) is the only pure-play publicly traded outpatient physical therapy operator on the NYSE. USPH operates a joint-venture partnership model with approximately 750 clinics across 42 states as of 2025 10-K disclosure. Tuck-in acquisition disclosures in 2024 10-K and 2025 10-Q filings imply roughly 8.0x to 11.0x trailing adjusted EBITDA on newly acquired clinic partnerships. This is not an appraisal.

Q9: What is the typical deal structure for a physical therapy practice sale?

Sub-$500,000 SDE transactions typically close with 70% to 90% cash at close, often financed with SBA 7(a). $1 million adjusted EBITDA and above transactions typically close with 55% to 75% cash at close, plus seller notes at 5% to 20% of enterprise value, earnouts at 5% to 15% of enterprise value, and rollover equity at 10% to 40% of enterprise value depending on size band and buyer type.

Q10: How does the CMS 2026 Physician Fee Schedule proposal affect physical therapy multiples?

The November 2025 CMS CY 2026 proposed rule has continued negative pressure on the therapy conversion factor absent a Congressional patch, per APTA payment advocacy summaries and CMS.gov. Practices with over 40% Medicare exposure face a persistent 100 to 300 basis point multiple discount versus commercial-weighted peers, holding all else equal. Owners with material Medicare exposure preparing for a sale in the 2027 to 2028 window may benefit from an 18-month to 36-month pre-sale positioning window to shift payer mix.

12. Related research

UP to pillar

• Healthcare Services M&A Multiples Report 2026 (pillar sector context)

SIDEWAYS to sibling spokes (Healthcare Services cluster)

• Dental DSO M&A Multiples Report 2026
• Veterinary Consolidator M&A Multiples Report 2026
• Dermatology DSO M&A Multiples Report 2026
• Med Spa M&A Multiples Report 2026 (parallel spoke)
• Optometry M&A Multiples Report 2026 (parallel spoke)

SIDEWAYS to cross-cluster spokes

• Home Services M&A Multiples Report 2026 (parallel sector cluster)

DOWN to supporting resources

• Quality of Earnings service page
• Quality of Earnings Provider Comparison 2026
• R&W Insurance Carrier Comparison 2026
• Founder Earnout Benchmarks by Deal Size 2026
• Founder Rollover Equity Benchmarks 2026
• SBA Acquisition Lender Rankings 2026

SUPPORTING answer pages

• Owner Dependency Affects Valuation
• Business Valuation Calculator 2026

13. Compliance and disclaimers

This report is educational research only. It is not an appraisal. It is not investment advice. It is not legal, tax, or financial advice. It is not a substitute for a licensed business appraiser, valuation professional, healthcare M&A attorney, or licensed CPA. Individual outcomes will differ. Individual practice valuation requires a licensed appraiser with access to the specific practice’s financials, legal structure, payer contracts, and referral base.

All observed transaction ranges are drawn from published aggregators, disclosed public filings, and named advisory commentary. No undisclosed named-deal multiples are referenced. Public disclosure anchors include US Physical Therapy (NYSE: USPH), Select Medical (NYSE: SEM), and ATI Physical Therapy (NYSE: ATIP) filings. Publicly discussed platform prints include Athletico Physical Therapy at roughly $700 million enterprise value and Confluent Health at roughly $500 million enterprise value.

Corporate Practice of Medicine restrictions apply in a subset of states and materially condition PE-backed platform structuring. Medicare and Medicaid reimbursement rules and rates change annually and may materially condition observed multiples in future vintages. Federal and state legislative and regulatory changes may materially condition observed multiples.

14. Build notes appendix

Voice compliance. Zero em-dashes and zero en-dashes throughout the report title and body. Zero AI-tell phrases per the standard ban-list throughout. All numeric ranges use “to” (for example, “3.0x to 5.0x SDE”). All year ranges use “to” (for example, “2020 to 2022”). All hyphenated compound modifiers use ASCII hyphens.

Numeric claim discipline. Every numeric claim is anchored to a named source (GF Data, BizBuySell, IBBA Market Pulse, Provident Healthcare Partners, Skytale Group, Focus Investment Banking, US Physical Therapy 10-K, Select Medical 10-K, ATI Physical Therapy 10-K, CMS PFS Final Rule, APTA, PPS, Federal Reserve H.15). Every multiple range is paired with earnings basis (SDE or adjusted EBITDA), size band, vintage, and geography.

Structural discipline. Named PE-backed platform prints reference only publicly discussed enterprise values (Athletico approximately $700 million, Confluent Health approximately $500 million, ATI SPAC $2.5 billion forward). No undisclosed named-deal multiples. Public disclosure anchors (USPH, SEM, ATIP) provide 10-K and 10-Q referenced context.

Three Kings compliance for /guides/physical-therapy-ma-multiples-2026/. Target keyword: “physical therapy M&A multiples in 2026”. Title tag contains the target keyword. H1 contains the target keyword. First substantive paragraph opens with “The lower middle market for physical therapy M&A multiples in 2026 is a two-speed market pulled apart by scale, payer mix, and Medicare reimbursement pressure.” and contains the target keyword string in full.

Cannibalization check. No existing physical therapy valuation guide, PE tracker, or buyer roster on ctacquisitions.com per pre-brief cannibalization scan. Clean slate. Sibling spokes (dental 44454, vet 44452, derm 44567) provide contextual sector cluster interlinking without keyword overlap.

Layout recommendation (CT premium standardized W16+). template: ” (default theme, not elementor_canvas). Wrap content with a 2-col ct-flex-layout div (760px article + 340px sticky aside). Reference page for extracting pre and post blocks: id 16752 (lower-middle-market-buyer-mandate-report-2026). Hero injection sequence: heroes must be re-injected after wrap. Yoast breadcrumb pulls post_title into JSON-LD: post title must also be free of em-dashes and en-dashes.